Evaluation of Multiple Sclerosis Progression Using Magnetic Resonance Imaging (MRI) to Monitor Disease Activity and Immune Measures

What this Trial Is About

Researchers are investigating the natural history and progression of multiple sclerosis (MS) using magnetic resonance imaging (MRI) and immunological measures. This study follows patients with definite MS or those with initial neurological symptoms consistent with MS, alongside a group of healthy volunteers for comparison. The study aims to understand disease activity by examining MRI changes, clinical features, and immunological and genetic factors, both before and after the use of approved disease-modifying therapies (DMT). Participants include untreated MS patients and those starting approved therapies. Untreated patients are studied longitudinally with various MRI techniques assessing lesion activity, brain atrophy, and axonal damage. Patients beginning therapy undergo monthly MRIs before treatment to assess disease activity and are followed during therapy to explore treatment mechanisms and response. Additionally, healthy volunteers are studied to establish normal imaging and immunological benchmarks. During the study, participants undergo clinical assessments, MRI scans, and immunological and genetic testing. Samples collected are cryopreserved for future biomarker research. The main outcome measured is the rate of change in new white matter lesions over time. Follow-up visits coincide with clinical care schedules, with optional research visits possible. The study includes long-term monitoring to better understand MS progression and therapy effects.

Magnetic Resonance Imaging (MRI) to Evaluate Activity of Multiple Sclerosis (MS)